{"schema_version":"secwatch.filing_event.v1","accession":"0000896622-22-000029","form_type":"8-K","ticker":"ATR","cik":"0000896622","company_name":"APTARGROUP, INC.","filed_at":"2022-10-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.931105+00:00","generated_at":"2026-06-23T00:36:11.279599+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"AptarGroup Q3 net income +15% to $54M; core sales +9%; adj EPS $0.95","bullets":["Reported net income $54M (+15%), EPS $0.81 (+16%) vs $0.70.","Adjusted EPS $0.95 (+12% vs $0.85), includes $0.05 one-time inflation payment.","Pharma core sales +20% driven by prescription and allergies; Food +Bev flat.","Q4 adjusted EPS guidance $0.73–$0.83, with $0.08 currency headwind.","Dividend $0.38/share payable Nov 16; $128M remaining for buybacks."],"urls":{"canonical":"https://secwatch.observer/filing/0000896622-22-000029","json":"https://secwatch.observer/filing/0000896622-22-000029.json","markdown":"https://secwatch.observer/filing/0000896622-22-000029.md","text":"https://secwatch.observer/filing/0000896622-22-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896622/000089662222000029/0000896622-22-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896622/000089662222000029/atr-20221027.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T00:36:11.279599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}